Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | CPX-351 in poor risk AML patients

Fabio Guolo • 11 Jun 2020
EHA 2020
Leukemia CPX-351 Cytarabine Daunorubicin

Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, discusses the use of CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin, in poor-risk acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Fabio Guolo

Selecting patients with secondary AML for CPX-351
1:14
Selecting patients with secondary AML for CPX-351
Fabio Guolo • 13 Jun 2025
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification
1:15
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification
Fabio Guolo • 13 Jun 2025
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML
1:19
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML
Fabio Guolo • 6 Dec 2024
Real-world evidence of the efficacy of CPX-351 in secondary AML
1:01
Real-world evidence of the efficacy of CPX-351 in secondary AML
Fabio Guolo • 6 Dec 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals